Hui Li Ding

US Patent:

8309614, Nov 13, 2012

Filed:

Apr 10, 2009

Appl. No.:

12/935110

Inventors:

Hui Ding - Los Angeles CA, US
Julia Y. Ljubimova - Studio City CA, US
Eggehard Holler - Los Angeles CA, US
Keith L. Black - Los Angeles CA, US

Assignee:

Cedars-Sinai Medical Center - Los Angeles CA

International Classification:

A61K 47/14
C07H 21/02

US Classification:

514772, 536 245, 977704, 977906

Abstract:

The invention relates to the use of Polycefin-LLL nanoconjugate as a means of cytoplasmic delivery of drugs. In one embodiment, the present invention provides a drug delivery molecule, comprising a polymerized carboxylic acid molecular scaffold covalently linked to L-leucylleucylleucine. In another embodiment, the Polycefin-LLL includes drug antisense morpholino oligos, targeting antibodies, and a pH-sensitive endosome escape unit. In addition, the drug could be siRNA, microRNA, and aptamer.

US Patent:

20200155593, May 21, 2020

Filed:

Jan 27, 2020

Appl. No.:

16/773769

Inventors:

- LOS ANGELES CA, US
Hui Ding - Los Angeles CA, US
Eggehard Holler - Los Angeles CA, US
Keith L. Black - Los Angeles CA, US
Julia Y. Ljubimova - Studio City CA, US

International Classification:

A61K 31/713
C07K 16/32
C07K 16/28

Abstract:

Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (β-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described.

US Patent:

20190060479, Feb 28, 2019

Filed:

Mar 3, 2017

Appl. No.:

16/081584

Inventors:

- Los Angeles CA, US
Keith L. BLACK - Los Angeles CA, US
Eggehard HOLLER - Los Angeles CA, US
Alexander LJUBIMOV - Studio City CA, US
Hui DING - Los Angeles CA, US

Assignee:

CEDARS-SINAI MEDICAL CENTER - Los Angeles CA

International Classification:

A61K 47/68
A61K 47/59
A61K 47/18
A61K 47/10
A61K 45/06
A61P 35/00

Abstract:

Nanoimmunoconjugates including a polymalic acid-based molecular scaffold, targeting ligands, anti-tumor immune response stimulators and anti-cancer agents are provided. Methods for treating cancer in a subject by administering the nanoimmunoconjugates that provide both systemic and local immune responses and synergistic anticancer effect are described.

US Patent:

20170340659, Nov 30, 2017

Filed:

Mar 2, 2017

Appl. No.:

15/447439

Inventors:

- Los Angeles CA, US
Hui Ding - Los Angeles CA, US
Eggehard Holler - Los Angeles CA, US
Keith L. Black - Los Angeles CA, US
Julia Y. Ljubimova - Studio City CA, US

International Classification:

A61K 31/713
C07K 16/28
C07K 16/32
A61K 39/00

Abstract:

Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (β-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described.

US Patent:

20140193398, Jul 10, 2014

Filed:

Jun 28, 2013

Appl. No.:

13/930533

Inventors:

- Los Angeles CA, US
Hui Ding - Los Angeles CA, US
Eggehard Holler - Los Angeles CA, US
Keith L. Black - Los Angeles CA, US
Julia Y. Ljubimova - Studio City CA, US

International Classification:

A61K 39/395
A61K 31/713

US Classification:

4241331, 514 44 A, 4241741, 514 193, 514 194, 514 195

Abstract:

Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (β-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described.